Health Canada has officially approved the following claims for Prenatis™ (Lactobacillus rhamnosus Rosell®-11 and Bifidobacterium bifidum HA-132).
- In conjunction with breastfeeding, helps support a healthy gut flora in newborns.
- Helps support vaginal health
- Helps support healthy vaginal flora
Solange Henoud, Vice President Regulatory and Compliance at Lallemand Health Solutions stated: “These new health claims provide evidence of our serious commitment to women’s health and validate years of research and innovation that aimed at supporting female health during pregnancy and demonstrating the power of breastfeeding in transmitting mother to baby benefits. The Prenatis™ blend has proven the establishment of a healthy foundation for the breastfed babies’ microflora, in addition to the benefits for the moms. We are very proud to offer a scientifically backed solution meeting high regulatory standards for such a vulnerable population”.
Élodie Aragon, Product Manager at Lallemand Health Solutions, added: “Prenatis™ has been studied in a large cohort of healthy pregnant women in their third trimester and their babies, showing significant results in maintaining a healthy pregnancy and establishing a healthy infant microbiome during the first months of life. These findings open new opportunities for our clients and inspire innovative product development
tailored to the needs of pregnant women.”
Prenatis™ represents a significant advancement in perinatal health, supporting maternal well-being and laying the foundation for a healthy infant microbiome during early life. It can be combined with other probiotic strains and enriched with essential nutrients such as vitamin B9 (folic acid). Prenatis™ is available in convenient formats, including sachets, sticks, orodispersible powders, and capsules in blisters or bottles—ensuring ease of use for expectant mothers.
